Back to search

Article

CD147 promotes cisplatin resistance in ovarian cancer by inhibiting FOXM1 degradation via PI3k/Akt-GSK3β pathway

2023-01-24

Abstract excerpt

CD147 is a transmembrane glycoprotein that is highly expressed in a number of human cancers, including ovarian cancer. The antibody drug Licartin®, which targets CD147, has been approved by the Chinese Food and Drug Administration (FDA) and entered clinical treatment. Some studies have shown that CD147 plays a role on drug resistance, but the molecular mechanism remains elusive. This study sought to investigate th...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
44e4fb7b-4672-57d2-9099-f38ebb534352
DOI
10.21203/rs.3.rs-2474599/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
CD147 promotes cisplatin resistance in ovarian cancer by inhibiting FOXM1 degradation via PI3k/Akt-GSK3β pathwayDOI 10.21203/rs.3.rs-2474599/v1
Select a neighboring publication to make it the new centre.